Antibodies in the treatment of aplastic anemia. | Aplastic Anemia and MDS International Foundation

Antibodies in the treatment of aplastic anemia.

Journal Title: 
Arch Immunol Ther Exp
Author(s): 
Gómez-Almaguer D, Jaime-Pérez JC, Ruiz-Arguelles GJ
Primary Author: 
Gómez-Almaguer D,
Original Publication Date: 
Saturday, February 4, 2012

Antibodies have been the cornerstone of treatment of acquired aplastic anemia for more than 25 years. Treatment with antithymocyte globulin (ATG) is considered pivotal and the addition of cyclosporine improves the overall response rate. This antibody is heterogeneous and horse ATG is apparently more effective than rabbit ATG. Several issues remain unsolved in relation to the combination of ATG and cyclosporine: cost, toxicity and late clonal disorders. In recent years, alternative immunosuppressive therapy has been proposed and new antibodies have emerged: porcine ATG, alemtuzumab, daclizumab, and rituximab. Experience with these antibodies is limited to a few studies with alemtuzumab being the most promising, but the results are interesting and provocative. More studies are needed to find the perfect antibody.

Bone Marrow Diseases: